Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Phenylephrine Ophthalmic Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil

NCT02946125
View directory record Official record
Conditions
Mydriasis
Interventions
MDD-administered EYN-1601, Phenylephrine 2.5% Eyedrop, Phenylephrine 10% Eyedrop
Combination Product · Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance

NCT04831047
View directory record Official record
Conditions
Ptosis, Eyelid, Conjunctiva Inflamed, Eye Manifestations
Interventions
Oxymetazoline hydrochloride 0.1% ophthalmic solution, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 1 Interventional

The Pathophysiology of Orthostatic Hypotension

NCT00748059
View directory record Official record
Conditions
Autonomic Nervous System Diseases, Orthostatic Hypotension, Dopamine Beta-Hydroxylase Deficiency, Orthostatic Intolerance
Interventions
Standing or upright tilt, Microneurography, QSweat, neck cuff stimulation, phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine, clonidine,yohimbine,metoclopramide,alpha-methyldopa, BodPod, Eye exam, Sleep study, Pain response testing, Metabolic chamber, Brain function studies, Bicycle Exercise Test
Procedure · Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis

NCT01848041
View directory record Official record
Conditions
Blepharoptosis
Interventions
RVL-1201, RVL-1201 Vehicle Placebo
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Morrow, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 6, 2026, 5:44 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Exploration of Pupil Dilation in Horner's Patients Taking Flomax

NCT03615508
View directory record Official record
Conditions
Horner Syndrome
Interventions
10% phenylephrine
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Not applicable Interventional

Study on Effective Mydriasis in Premature Infants

NCT01054027
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
1% phenylephrine and 0.2% cyclopentolate
Drug
Lead sponsor
Georgetown University
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2010 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes

NCT02965924
View directory record Official record
Conditions
Assess Phenylephrine on EVP and IOP
Interventions
Phenylephrine 2.5%
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

NCT03751098
View directory record Official record
Conditions
Mydriasis
Interventions
Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

Study of Safety of RVL-1201 in Treatment of Blepharoptosis

NCT03536949
View directory record Official record
Conditions
Blepharoptosis
Interventions
RVL-1201, Vehicle ophthalmic solution
Drug · Other
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
9 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
35
States / cities
Phoenix, Arizona • Garden Grove, California • Mission Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 2 Interventional

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

NCT01275105
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Results available

Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation

NCT05890027
View directory record Official record
Conditions
Ptosis, Eyelid
Interventions
Phenylephrine Ophthalmic, Eyelid Tape
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 6, 2026, 5:44 PM EDT
Not yet recruiting Phase 4 Interventional

Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients

NCT06366217
View directory record Official record
Conditions
Dilation, Pupil Reaction Absent
Interventions
MydCombi Device, MydCombi Drug
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 6, 2026, 5:44 PM EDT
Not listed Phase 4 Interventional Results available

Descemet Endothelial Thickness Comparison Trial

NCT02373137
View directory record Official record
Conditions
Keratoplasty, Grafting, Corneal, Transplantation, Corneal, Transplantation, Cornea, Keratoplasty, Lamellar
Interventions
DSAEK, DMEK, Endoserter, Prednisolone, Ofloxacin, Tropicamide, Phenylephrine, Jones Tube
Procedure · Device · Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
Palo Alto, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 6, 2026, 5:44 PM EDT
Not listed Early Phase 1 Interventional

Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%

NCT06539637
View directory record Official record
Conditions
Cataract
Interventions
OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}, Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop
Combination Product · Other
Lead sponsor
DHS Consulting
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Westbury, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis

NCT03565887
View directory record Official record
Conditions
Blepharoptosis
Interventions
RVL-1201, Vehicle ophthalmic solution
Drug · Other
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
9 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
36
States / cities
Phoenix, Arizona • Garden Grove, California • Mission Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 6, 2026, 5:44 PM EDT
Not yet recruiting Not applicable Interventional

Robotic Systems Evaluation for Peripheral Pulmonary Lesions (RISE Trial)

NCT07735611
View directory record Official record
Conditions
Lung; Node
Interventions
RAB via the Monarch platform, RAB via the ION platform
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Brimonidine

NCT03959176
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Brimonidine, Tropicamide, Phenylephrine Ophthalmic Product
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients

NCT03139708
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Alphagan, Phenylephrine, Tropicamide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

NCT05223478
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle
Drug
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Longwood, Florida • Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2023 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Impact of aKwa Skincare System on Skin Health

NCT05476406
View directory record Official record
Conditions
Sin Health, Skin Hydration, Skin Wrinkles, Skin Porphyrins, Facial Skin Red Spots, Facial Skin Red Vasculature
Interventions
äKwä skincare system products, competitor products (control)
Other
Lead sponsor
4Life Research, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Sandy City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily

NCT04983589
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine HCl, Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 55 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Bakersfield, California • Glendale, California • Inglewood, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

NCT03751631
View directory record Official record
Conditions
Mydriasis
Interventions
Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE), Tropicamide 1% ophthalmic solution (TR), Phenylephrine 2.5% ophthalmic solution (PE)
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 6, 2026, 5:44 PM EDT
Terminated Not applicable Interventional Results available

Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy

NCT01982383
View directory record Official record
Conditions
Central Serous Chorioretinopathy
Interventions
Micropulse Laser Treatment, No treatment
Device · Other
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Sep 6, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation

NCT06217796
View directory record Official record
Conditions
Mydriasis
Interventions
MydCombi
Combination Product
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 6, 2026, 5:44 PM EDT